<DOC>
	<DOCNO>NCT00003545</DOCNO>
	<brief_summary>Phase II trial study effectiveness 506U78 treat patient refractory relapse acute lymphoblastic leukemia lymphoblastic lymphoma . Drugs use chemotherapy use different way stop cancer cell divide stop grow die .</brief_summary>
	<brief_title>506U78 Treating Patients With Refractory Relapsed Acute Lymphoblastic Leukemia Lymphoblastic Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : I . Determine complete partial remission rate , well remission duration , patient refractory relapse T-cell acute lymphoblastic leukemia lymphoblastic lymphoma receive 506U78 alternate day schedule ( day 1 , 3 , 5 ) . II . Determine safety toxicity 506U78 administered schedule patient population . OUTLINE : Patients receive 506U78 IV 2 hour day 1 , 3 , 5 . If residual leukemia/lymphoma present day 22 , patient receive second course 506U78 . If day 22 marrow hypocellular , repeat bone marrow biopsy obtain day 29 ass response . For day 22 29 marrow complete response , patient receive 506U78 two course day 1 , 3 , 5 , administer every 21 day . Patients follow every 3 month 1 year , every 6 month maximum 10 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm diagnosis Tcell acute lymphoblastic leukemia ( ALL ) lymphoblastic lymphoma ( LBL ) Leukemia lymphoma cell express least two follow cell surface antigens : CD1a , CD2 , CD3 ( surface cytoplasmic ) , CD4 , CD5 , CD7 , CD8 Leukemia cell negative myeloperoxidase Sudan Black B If T cell marker present CD4 CD7 , leukemic cell demonstrate lack myeloid marker CD33 and/or CD13 Refractory least one induction treatment regimen first later relapse achieve complete remission No CNS leukemia lymphoma require intrathecal craniospinal radiotherapy PATIENT CHARACTERISTICS : Age : 16 Bilirubin great 2 time upper limit normal ( unless due leukemia ) Creatinine clearance least 50 mL/min ( unless due leukemia ) No neurologic toxicity grade 3 great prior treatment ALL/LBL No preexist neuropathy grade 2 great regardless causality No history seizure disorder Not pregnant nursing Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : No concurrent erythropoietin No concurrent chemotherapy No concurrent dexamethasone steroidal antiemetics No concurrent hormone therapy , except nondiseaserelated condition</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2007</verification_date>
	<keyword>recurrent childhood acute lymphoblastic leukemia</keyword>
	<keyword>recurrent childhood lymphoblastic lymphoma</keyword>
	<keyword>recurrent adult acute lymphoblastic leukemia</keyword>
	<keyword>T-cell childhood acute lymphoblastic leukemia</keyword>
	<keyword>T-cell adult acute lymphoblastic leukemia</keyword>
	<keyword>recurrent adult lymphoblastic lymphoma</keyword>
	<keyword>recurrent adult T-cell leukemia/lymphoma</keyword>
</DOC>